Kemai Bio CEO Wang Tianyuan Joins IBI EXPO Suzhou 2025 as Co-Organizer of AI-Driven Innovative Drug Discovery Forum

Nov 08, 2024 09:01 CST Updated 09:01

Clickmab

Early-stage Antibody Drug Developer

A year's plan starts in spring, the beginning of the four seasons. With the orderly arrival of spring, it is a good time to embark on a new journey.March 1, 2025 to March 2, 2025，IBI EXPO 2025 (3rd) Biopharmaceutical Innovation Industry ConferenceWill be inSuzhou International Expo CenterGrandly held.

Conference FocusCell therapy, gene therapy, novel antibody drugs, stem cells and regenerative medicine, gene editing, nucleic acid drugs, exosomes, novel deliveryetc.In the field of cutting-edge biopharmaceutical technology, fromNew Drug R&D, Non-clinical Evaluation, CMC Development, Drug Registration, Clinical Trials, Commercializationetc.The entire lifecycle of biopharmaceuticals will be covered, and leading companies from various细分fields in China, emerging enterprises, as well as representatives of leading companies that have made significant progress in the past year will be invited to present an unprecedented annual event in the field of biopharmaceutical innovation for the industry.

To promote the development of the industry,IBI EXPO 2025 (3rd) Biopharmaceutical Innovation Industry ConferenceTheAI-Assisted Innovative Drug R&D Forum, SpecialDrug Discovery and DesignSub-venue, andInvitedClickmab CEO Tianyuan WangAs the co-planner, the focus will be on exploring AI-assisted innovative drug development.Frontier Advances, Technical Challenges, and Future Prospects。

Introduction to the Planner

Swipe up to view

Tianyuan Wang, CEO of Clickmab

Bachelor's degree from the University of Science and Technology of China, during the Ph.D. period engaged in chemical biology, directed evolution of enzymes, and related research at the Institute of Biophysics, Chinese Academy of Sciences. As an assistant researcher, engaged in research and application of computational design and modification of biomacromolecules based on artificial intelligence.

At Crystal Pharmatech and Clickmab, Dr. Tianyuan Wang led a team in independently developing an AI antibody de novo design platform based on deep learning and computational biology, as well as a computational platform for the design, screening, and optimization of biomacromolecules such as proteins and peptides. In multiple external pharmaceutical company collaborations and internal R&D projects, they delivered drug molecules with required activity and druggability, achieving AI-enabled biopharmaceuticals.

With多年的经验 in AI algorithm development, practical implementation of AI in biopharmaceutical R&D, team management, and incubation of projects driven by cutting-edge technology as well as industry-academia-research transformation.

AI-Assisted Innovative Drug R&D Forum

Key Content and Hot Topics

AI+CAR-T Cell Therapy

AI + Peptide/Protein Drugs, Tumor Neoantigens

AI+RNA Structure Prediction

GPCR Antibody Drug Development

Establishment of mRNA Personalized Cancer Vaccine Database and Its Integration with AI

Roundtable Discussion:Accelerate the Application and Implementation of AI Technology in Biologic Drug Innovation

This forum is for enterprises and scientific research institutions guestsOpen Report Seat, to showcase the latest achievements to the industry, create more cooperation opportunities, and welcome registrations!